Nivolumab, the first monoclonal antibody against the immune checkpoint inhibitor programmed cell death protein-1 (PD-1), is approved for clinical use for the treatment of advanced melanoma and metastatic non-small cell lung cancer. Given their mechanism, these treatments also have the potential to generate a host of immune toxicities, otherwise known as immune-related adverse events (irAEs). Dermatologic toxicities are amongst one of the most prevalent irAEs, seen in approximately a third of all patients treated with immunotherapies \[[@B1]\]. We report the case of a 74-year-old woman with a history of non-small cell lung cancer treated with nivolumab 10 months prior to presentation who developed painful nodules, bullae, and a scaly rash on her extremities.

Case Report {#sec1_1}
===========

A 74-year old woman presented with non-small cell lung cancer treated initially by wedge resection, chemotherapy, and radiation. Nivolumab was initiated after a subsequent metastasis to the left lower lobe and mediastinal lymph nodes. Her treatment course was complicated by thyroiditis and large oral and vaginal ulcers, leading to discontinuation of nivolumab. Treatment with doxycycline led to the resolution of the patient\'s mucosal ulcerations. Four months later, the patient noted an acute eruption consisting of painful, friable pruritic nodules on her extremities. Over the course of several weeks, she developed lesions of varying morphologies: multiple bright pink papules with a white peripheral border, large hyperkeratotic nodules and plaques, some with central ulceration, and several tense bullae along bilateral palms and soles (Fig. [1](#F1){ref-type="fig"}). Several hyperkeratotic lesions were treated with liquid nitrogen cryotherapy and intralesional triamcinolone with minimal effect.

Biopsies were performed of lesions of varying morphologies. Histopathologic examination of the hyperkeratotic lesions revealed endophytic squamous proliferation with a lichenoid inflammatory infiltrate, consistent with hypertrophic lichen planus (LP). The buccal mucosa biopsy revealed ulcerated squamous mucosa with dense lichenoid lymphoplasmacytic infiltrate. Biopsy of a vesicular lesion revealed subepithelial vesicle with associated epidermal hyperplasia, lichenoid interface change, and perivascular lymphocytic and neutrophilic infiltrate with pigment incontinence (Fig. [2](#F2){ref-type="fig"}), consistent with lichenoid hypersensitivity reaction, bullous LP, or bullous pemphigoid. Direct immunofluorescence examination was negative for IgG and IgM reactivity along the basement membrane zone. These findings were felt to be consistent with a nivolumab-induced lichenoid reaction.

The patient was started on intravenous methylprednisolone 60 mg twice daily, which was eventually transitioned to oral prednisone 80 mg daily on discharge. She continued to receive wound care with topical clobetasol 0.05% ointment and non-adherent bandages, and her pain was well-controlled with hydromorphone. Two weeks after discharge, she showed significant improvement in pain and decrease in size and number of hyperkeratotic papules and plaques. She was eventually trialed to acitretin 10 mg every other day for possible flare prevention but discontinued due to nausea.

Discussion {#sec1_2}
==========

IrAEs in the context of immune checkpoint inhibitors are driven by blockade of T-cell suppression and modulation of immunosurveillance \[[@B2], [@B3], [@B4]\]. Blockade of the programmed cell death receptor on activated T cells leads to an overall increased inflammatory response to antigens and tumors, thus shifting the balance to an anti-tumor response \[[@B3]\]. Dermatologic irAEs typically occur within days or weeks of treatment, though onset may be delayed, appearing 3--6 months after initiating the anti-PD-1 agent \[[@B5]\]. A delayed effect of immune checkpoint antibodies, as seen in our patient, can also occur sometimes up to 1 year after the initiation of anti-PD-1 treatment, so keeping a high clinical suspicion for anti-PD-1 cutaneous toxicity is essential \[[@B6]\]. To our knowledge, the concomitant manifestations of lichenoid processes, including LP-like lesions, keratoacanthomas, and bullous LP, in an individual patient have not been reported.

A case series of three patients receiving pembrolizumab for metastatic melanoma described the development of erythematous to violaceous papules and plaques 7--9 weeks after drug initiation. A single-institution cohort study of 82 patients on single-agent anti-PD-1 therapy for metastatic melanoma identified lichenoid reaction development in 14 patients. Of these patients, 17% developed lichenoid reactions, 17% developed eczema, and 15% developed vitiligo \[[@B7]\]. In addition, two patients developed all 3 cutaneous toxicities, and 9 developed certain combinations of all three events \[[@B7]\].

Our patient also developed hypertrophic nodules on a background of lichenoid drug reaction. A recent case series of 3 patients describes pembrolizumab-associated eruptive keratoacathomas that resolved with monthly intralesional steroid injections (20 mg/mL), adjuvant topical treatment every other day, and liquid nitrogen cryotherapy \[[@B8]\]. In this series, all patients achieved complete response after 1 month of treatment. While our patient reported minimal improvement in her hands one week after the initial 20 mg/mL steroid injections and cryotherapy, these treatments were stopped when she developed bullous lesions. It is possible that continued serial treatments would have led to resolution of these lesions.

Finally, our patient additionally had bullous lesions on examination. A number of reports have recently reported PD1-inhibitor-induced bullous pemphigoid \[[@B9], [@B10], [@B11], [@B12], [@B13]\]. At a single institution, bullous eruptions were seen in 9 (1%) of 853 patients treated with anti-PD1 therapy over a period of 2 years. In a case series of 5 patients with bullous lesions, 4 were found to have bullous pemphigoid and were successfully treated with systemic and topical steroids \[[@B12]\]. The negative direct immunofluorescence in our patient indicates that the bullae represented a component of the lichenoid drug reaction.

Conclusion {#sec1_3}
==========

Although each individual morphology has been reported in the setting of PD-1 inhibitor therapy, we report the first case of LP-like lesions, keratoacanthomas, and bullous LP morphologies arising concomitantly after nivolumab treatment. The inflammatory infiltrate on biopsy and their complete response to intravenous corticosteroids suggest that they represent irAE to nivolumab. Patients receiving nivolumab will need to be closely monitored for occurrence of irAEs. Further research is necessary to understand the immunologic mechanism underlying nivolumab-induced cutaneous toxicity.
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![Different clinical morphologies. Tense bullous lesions on palms (**a**) and soles (**b**). **c** Large hyperkeratotic nodules and plaques, some with central ulceration. **d** Pink flat papules with white peripheral border, some with scale.](dpa-0006-0255-g01){#F1}

![Left medial ankle biopsy. Epidermal hyperplasia with lichenoid inflammatory infiltrate and subepidermal bulla. **a** Low-power view (hematoxylin and eosin, ×100). **b** High-power view (hematoxylin and eosin, ×400).](dpa-0006-0255-g02){#F2}
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